In 112 metastatic melanoma patients starting treatment with anti–PD-1 therapy, Gopalakrishnan, V., et al. indicated that the gut microbiome might modulate responses to anti-PD-1 immunotherapy. This evidence concerns the gene PDCD1 and metastatic melanoma.